MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP)
Clinical trials for MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP) explained in plain language.
Never miss a new study
Get alerted when new MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP) trials appear
Sign up with your email to follow new studies for MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets root cause of rare overgrowth diseases in kids and adults
Disease control Recruiting nowThis study tests a new drug, RLY-2608, designed to block a faulty protein that causes abnormal growth in people with PIK3CA-related overgrowth spectrum (PROS) and related malformations. The trial enrolls 277 adults and children to see if the drug can safely shrink overgrown tissu…
Matched conditions: MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP)
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for rare brain disorder: drug trial targets MCAP symptoms
Disease control Recruiting nowThis study tests a drug called alpelisib in 20 people aged 2 to 40 with MCAP syndrome, a rare condition causing an enlarged brain and developmental delays. For the first 6 months, some get the drug and some get a placebo to see if it improves daily living skills like communicatio…
Matched conditions: MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP)
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated May 11, 2026 20:53 UTC